About IVIRMA Global
IVI and RMA, two global leaders in reproductive medicine, research, assisted reproduction, and patient-centered care, became a single global company in 2017.
Infertility Knows No Boundaries
It’s estimated that 10% of the world’s childbearing population is struggling to get pregnant or stay pregnant. Whether you’re from Basking Ridge, NJ or Madrid, ES the dream of having a family sometimes needs a little help to become a reality. With the right team of global experts in the field, the safest and most innovative solutions, and commitment to success, you have reason to have hope.
Evidence-based Fertility Care
“As one unified global entity, RMA is committed to providing evidence-based fertility solutions with the greatest chance of success in the shortest time necessary to patients seeking treatment anywhere in the world. In 2018, patients came to RMA from over 30 U.S. states and 40 countries. Now, together with IVI, RMA is better positioned to bring new hope to patients around the globe.” – Dr. Richard T. Scott, Jr., founding partner and laboratory director of RMA New Jersey.
75 Locations in 9 Countries
IVI-RMA Global and its affiliated practices employ nearly 2,400 people across 75 locations around the world, maintaining a team of over 200 physicians, and over 300 scientists and researchers. IVI-RMA Global and its board of directors, comprised of the founding partners of IVI and RMA, oversee several different international business units.
Unparalleled Experience & Expertise
“I have known Dr. Scott for many years, and we admire and respect each other. I have always pursued the goal of introducing our company to the United States, and today I am pleased we have made it. The key to achieve this step was RMA. We share much of the same medical, scientific and business values and interests. This alliance will allow us to take full advantage of the expertise, experience and distinguishing elements of both companies for the benefit of our patients and employees,” offered Dr. Antonio Pellicer, President, IVI.